Please Wait.....
Report
Latent TB Testing Market by Test Type (Tuberculin Skin Test/TST, IGRA Test), Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living with HIV), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2029
Market Report I 2024-11-01 I 261 Pages I MarketsandMarkets
The latent TB testing market will rise in value from estimated USD 582.5 million in 2024 to USD 773.4 million in 2029, at a CAGR of 5.8% over the forecast period. Increased funding and grants for TB control programs across the globe have emerged as an important growth factor in the latent TB testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of TB, especially in terms of early detection and prevention. These funds are being channeled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of latent TB. Apart from that, research grants and international collaborations are also enabling TB testing integration into routine healthcare services. Thus, this growing funding is rendering latent TB tests available and enhancing the efforts to control TB globally. This, in turn, is fuelling the growth of the global latent TB testing market.
"Interferon gamma release assay (IGRA) segment is expected to have the fastest growth rate in the latent TB testing market, by test type, during the forecast period."
The latent TB testing market is segmented into tuberculin skin test (TST) and interferon gamma release assay (IGRA), based on test type. Interferon gamma release assay (IGRA) tests are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy than conventional tuberculin skin tests (TST); IGRA tests do not suffer from interference by prior BCG vaccination, which can cause false positives for TST. Thus, IGRA is preferred in populations that have high BCG vaccination coverage. Furthermore, IGRA tends to offer faster and more consistent results, meaning that patients require fewer visits, enhancing overall efficiency in testing. Growing penetration of these tests in high-risk populations, such as patients who are immunocompromised and health care workers, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in TB and advancements in diagnostics are also driving the high growth of the IGRA test segment in the latent TB testing market.
"Household contacts with pulmonary TB segment accounted for the highest growth rate in the latent TB testing market, by application, during the forecast period."
Based on application, the latent TB testing market is bifurcated into household contacts (HHC) with pulmonary tuberculosis (TB)/household contacts (HHC) of tuberculosis (TB) patients, people living with HIV, and other applications. The household contacts with pulmonary TB application segment is expected to have the highest CAGR during the forecast period. Individuals in close contact with a TB patient have a much higher probability of becoming infected with latent TB, which is the reason why regular screenings are crucial in being able to diagnose the illness early and intervene by taking preventive measures. Increasing recognition of the critical role that latent TB testing plays among high-risk groups by healthcare providers and public health agencies also drives the need for accurate latent TB diagnostics. In addition, screening of contacts across the households by the governments and TB control programs in efforts to curb latent infections from becoming active TB is further driving growth in the market segment. Collectively, all these factors are contributing to the fast growth of this application within the latent TB testing market.
"Asia Pacific: The fastest-growing region in latent TB testing market."
The worldwide market for latent TB testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drive the need for essential latent TB screening and management. Growth in government and international organization funding and campaigns against TB has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of latent TB has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the latent TB testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the latent TB testing market in the Asia Pacific region.
The break-up of the profile of primary participants in the latent TB testing market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%
The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US), bioMerieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), ARKRAY, Inc. (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika GmbH (Germany), Boditech Med Inc. (South Korea), Bioneovan Co., Ltd (China), and Biopanda Reagents Ltd (UK).
Research Coverage:
This research report categorizes the latent TB testing market by test type (tuberculin skin test (TST) and interferon gamma release assay (IGRA)), by application (household contacts with pulmonary TB, people living with HIV, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the latent TB testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the latent TB testing market. Competitive analysis of upcoming startups in the latent TB testing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall latent TB testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising incidence of latent tuberculosis, widespread use of BCG vaccine, and increased funding and grants for TB control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the latent TB testing market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the latent TB testing market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the latent TB testing market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the latent TB testing market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), and Endo, Inc. (US).
1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.3 STUDY SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 INCLUSIONS & EXCLUSIONS 27
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 28
1.4 STAKEHOLDERS 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.1.1 SECONDARY DATA 30
2.1.1.1 Key secondary sources 30
2.1.1.2 Key data from secondary sources 31
2.1.1.3 Objectives of secondary research 31
2.1.2 PRIMARY DATA 32
2.1.2.1 Key primary sources 32
2.1.2.2 Key data from primary sources 33
2.1.2.3 Key industry insights 34
2.1.2.4 Breakdown of primaries 34
2.1.2.4.1 Breakdown of primary interviews: supply & demand-side 34
2.1.2.4.2 Breakdown of primary interviews: by company type, designation, and region 35
2.2 MARKET SIZE ESTIMATION 35
2.2.1 BOTTOM-UP APPROACH 36
2.2.1.1 Company revenue estimation approach 36
2.2.1.2 Presentations of companies and primary interviews 36
2.2.1.3 Growth forecast 37
2.2.1.4 CAGR projections 37
2.2.2 TOP-DOWN APPROACH 37
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 39
2.4 MARKET SHARE ANALYSIS 39
2.5 ASSUMPTIONS 40
2.5.1 STUDY ASSUMPTIONS 40
2.5.2 GROWTH RATE ASSUMPTIONS 40
2.6 LIMITATIONS 41
2.7 RISK ASSESSMENT 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 46
4.1 LATENT TB TESTING MARKET OVERVIEW 46
4.2 LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 46
4.3 LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029 47
4.4 LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029 47
4.5 LATENT TB TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 50
5.2.1.1 Rising incidence of latent tuberculosis 50
5.2.1.2 Widespread use of BCG vaccine 51
5.2.1.3 Increased funding and grants for TB control programs 52
5.2.2 RESTRAINTS 53
5.2.2.1 Unfavorable reimbursement scenario 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Growth opportunities in emerging economies 53
5.2.4 CHALLENGES 54
5.2.4.1 Changing regulatory landscape 54
5.2.4.2 Operational barriers and labor shortage 54
5.3 PRICING ANALYSIS 54
5.3.1 AVERAGE SELLING PRICE, BY PRODUCT 55
5.3.2 INDICATIVE PRICE OF IGRA TESTS, BY REGION 55
5.4 PATENT ANALYSIS 56
5.4.1 LIST OF MAJOR PATENTS 58
5.5 VALUE CHAIN ANALYSIS 59
5.6 SUPPLY CHAIN ANALYSIS 60
5.7 TRADE ANALYSIS 61
5.7.1 IMPORT DATA 62
5.7.2 EXPORT DATA 62
5.8 ECOSYSTEM ANALYSIS 63
5.8.1 ROLE IN ECOSYSTEM 64
5.9 PORTER'S FIVE FORCES ANALYSIS 64
5.9.1 THREAT OF NEW ENTRANTS 65
5.9.2 THREAT OF SUBSTITUTES 65
5.9.3 BARGAINING POWER OF BUYERS 66
5.9.4 BARGAINING POWER OF SUPPLIERS 66
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 67
5.10.2 KEY BUYING CRITERIA 67
5.11 REGULATORY ANALYSIS 68
5.11.1 REGULATORY LANDSCAPE 68
5.11.1.1 North America 68
5.11.1.1.1 US 68
5.11.1.1.2 Canada 68
5.11.1.2 Europe 69
5.11.1.2.1 Germany 69
5.11.1.2.2 UK 70
5.11.1.2.3 France 70
5.11.1.2.4 Italy 70
5.11.1.2.5 Spain 70
5.11.1.3 Asia Pacific 71
5.11.1.3.1 China 71
5.11.1.3.2 Japan 71
5.11.1.3.3 India 71
5.11.1.3.4 Australia 72
5.11.1.3.5 South Korea 72
5.11.1.3.6 Singapore 73
5.11.1.4 Latin America 73
5.11.1.4.1 Brazil 73
5.11.1.4.2 Mexico 74
5.11.1.5 Middle East 74
5.11.1.5.1 Africa 74
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
5.11.2.1 North America 74
5.11.2.2 Europe 75
5.11.2.3 Asia Pacific 75
5.11.2.4 Latin America 76
5.11.2.5 Rest of the world 76
5.12 TECHNOLOGY ANALYSIS 76
5.12.1 KEY TECHNOLOGIES 77
5.12.1.1 Tuberculin skin test 77
5.12.2 COMPLEMENTARY TECHNOLOGIES 77
5.12.2.1 Interferon gamma released assay 77
5.13 KEY CONFERENCES AND EVENTS, 2024-2025 78
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79
5.15 INVESTMENT & FUNDING SCENARIO 79
5.16 CASE STUDY ANALYSIS 80
5.16.1 CASE STUDY 1: EXPLORING CYTOKINE USAGE IN MONITORING LTBI TREATMENT 80
5.16.2 CASE STUDY 2: ASSESSING DIAGNOSTIC ACCURACY OF ESAT6-CFP10 (EC) SKIN TEST FOR LTBI DETECTION 81
5.16.3 CASE STUDY 3: EVALUATING MTB-SPECIFIC CYTOKINE RESPONSES FOR ENHANCED LTBI DETECTION IN HEU INFANTS 81
5.17 LATENT TB CONTROL STRATEGIES IN MAJOR COUNTRIES 82
5.17.1 NORTH AMERICA 82
5.17.1.1 US 82
5.17.1.2 Canada 83
5.17.2 EUROPE 83
5.17.2.1 Germany 83
5.17.2.2 UK 84
5.17.3 ASIA PACIFIC 84
5.17.3.1 Japan 84
5.17.3.2 China 85
5.17.3.3 India 86
5.17.3.4 Singapore 87
5.18 IMPACT OF AI ON LATENT TB TESTING MARKET 87
5.18.1 KEY USE CASES 89
6 LATENT TB TESTING MARKET, BY TEST TYPE 90
6.1 INTRODUCTION 91
6.2 IGRA 91
6.2.1 HIGHER SPECIFICITY AND ACCURACY TO BOOST MARKET SEGMENT 91
6.3 TST 96
6.3.1 COST-EFFECTIVENESS TO PROPEL MARKET GROWTH 96
7 LATENT TB TESTING MARKET, BY APPLICATION 101
7.1 INTRODUCTION 102
7.2 PEOPLE LIVING WITH HIV 102
7.2.1 RISING RATES OF TB-HIV COINFECTION TO PROPEL GROWTH 102
7.3 HOUSEHOLD CONTACTS (HHC) WITH PULMONARY TUBERCULOSIS (TB)/ HOUSEHOLD CONTACTS (HHC) OF TUBERCULOSIS (TB) PATIENTS 106
7.3.1 NEED FOR ROUTINE SCREENING FOR HOUSEHOLD CONTACTS TO BOOST SEGMENT 106
7.4 OTHER APPLICATIONS 110
8 LATENT TB TESTING MARKET, BY END USER 115
8.1 INTRODUCTION 116
8.2 DIAGNOSTIC LABORATORIES 116
8.2.1 WELL-DEVELOPED INFRASTRUCTURE AND CAPABILITIES TO SUPPORT DEMAND FOR TESTING METHODS 116
?
8.3 HOSPITALS & CLINICS 120
8.3.1 GROWING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT 120
8.4 ACADEMIC & RESEARCH INSTITUTES 124
8.4.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH 124
8.5 OTHER END USERS 127
9 LATENT TB TESTING MARKET, BY REGION 131
9.1 INTRODUCTION 132
9.2 NORTH AMERICA 132
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 133
9.2.2 US 136
9.2.2.1 US to dominate North American latent TB testing market 136
9.2.3 CANADA 140
9.2.3.1 Improved screening and treatment for latent TB to drive market 140
9.3 ASIA PACIFIC 142
9.3.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 143
9.3.2 CHINA 146
9.3.2.1 Growing public access to modern healthcare to fuel market growth 146
9.3.3 JAPAN 149
9.3.3.1 Presence of universal healthcare reimbursement policy to drive market 149
9.3.4 INDIA 151
9.3.4.1 High TB burden and growing government initiatives to drive demand for latent TB screening 151
9.3.5 SOUTH KOREA 154
9.3.5.1 Rising healthcare spending in innovative diagnostic technologies to support market growth 154
9.3.6 AUSTRALIA 157
9.3.6.1 Diverse immigrant population to fuel demand for latent TB screening 157
9.3.7 SINGAPORE 159
9.3.7.1 Enhanced healthcare infrastructure to propel market growth 159
9.3.8 REST OF ASIA PACIFIC 162
9.4 EUROPE 164
9.4.1 EUROPE: MACROECONOMIC OUTLOOK 164
9.4.2 UK 167
9.4.2.1 Growing number of diagnostic centers to fuel market 167
9.4.3 FRANCE 169
9.4.3.1 Presence of robust healthcare system to augment market growth 169
9.4.4 GERMANY 171
9.4.4.1 Higher healthcare spending and favorable government policies to favor market growth 171
?
9.4.5 SPAIN 174
9.4.5.1 Improving healthcare infrastructure to drive demand 174
9.4.6 ITALY 176
9.4.6.1 Improved quality of medical care to spur market growth 176
9.4.7 BELGIUM 178
9.4.7.1 Targeted screening for high-risk groups to fuel demand 178
9.4.8 SWEDEN 180
9.4.8.1 Growing immigrant population from high-prevalence regions to propel demand 180
9.4.9 DENMARK 182
9.4.9.1 Importance of latent TB testing in public health strategy to support market growth 182
9.4.10 REST OF EUROPE 184
9.5 LATIN AMERICA 186
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 187
9.5.2 BRAZIL 189
9.5.2.1 Developed public health systems and improving healthcare infrastructure to favor market growth 189
9.5.3 MEXICO 191
9.5.3.1 Modernization of healthcare infrastructure to augment market growth 191
9.5.4 REST OF LATIN AMERICA 194
9.6 MIDDLE EAST & AFRICA 196
9.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 196
9.6.2 SOUTH AFRICA 198
9.6.2.1 Rising government initiatives for TB screening to augment market growth 198
9.6.3 SAUDI ARABIA 201
9.6.3.1 Enhancements in healthcare infrastructure to support market growth 201
9.6.4 UAE 203
9.6.4.1 UAE ranks among the world's leading countries with low TB rates 203
9.6.5 KUWAIT 205
9.6.5.1 Expansion of healthcare infrastructure to augment market growth 205
9.6.6 REST OF MIDDLE EAST & AFRICA 207
10 COMPETITIVE LANDSCAPE 210
10.1 INTRODUCTION 210
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 210
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LATENT TB TESTING MARKET 210
10.3 REVENUE SHARE ANALYSIS 212
10.4 MARKET SHARE ANALYSIS 213
10.4.1 MARKET SHARE ANALYSIS, BY REGION 215
10.4.1.1 North America 215
10.4.1.2 Europe 215
10.4.1.3 Asia Pacific 216
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 216
10.5.1 STARS 216
10.5.2 EMERGING LEADERS 216
10.5.3 PERVASIVE PLAYERS 216
10.5.4 PARTICIPANTS 216
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 218
10.5.5.1 Company footprint 218
10.5.5.2 Test type footprint 218
10.5.5.3 Application footprint 218
10.5.5.4 Region footprint 219
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 219
10.6.1 PROGRESSIVE COMPANIES 219
10.6.2 RESPONSIVE COMPANIES 219
10.6.3 DYNAMIC COMPANIES 219
10.6.4 STARTING BLOCKS 219
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 221
10.7.1 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023 221
10.8 VALUATION & FINANCIAL METRICS 222
10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 223
10.9.1 QIAGEN 223
10.9.2 REVVITY 223
10.9.3 BIOMERIEUX 224
10.10 COMPETITIVE SCENARIO 224
10.10.1 PRODUCT LAUNCHES 224
10.10.2 DEALS 225
11 COMPANY PROFILES 227
11.1 KEY PLAYERS 227
11.1.1 QIAGEN 227
11.1.1.1 Business overview 227
11.1.1.2 Products offered 228
11.1.1.3 Recent developments 229
11.1.1.3.1 Product launches & approvals 229
11.1.1.3.2 Deals 229
11.1.1.3.3 Expansions 230
11.1.1.4 MnM view 230
11.1.1.4.1 Right to win 230
11.1.1.4.2 Strategic choices 230
11.1.1.4.3 Weaknesses & competitive threats 230
?
11.1.2 REVVITY (OXFORD IMMUNOTEC) 231
11.1.2.1 Business overview 231
11.1.2.2 Products offered 232
11.1.2.3 Recent developments 233
11.1.2.3.1 Product launches & approvals 233
11.1.2.4 MnM view 233
11.1.2.4.1 Right to win 233
11.1.2.4.2 Strategic choices 233
11.1.2.4.3 Weaknesses & competitive threats 234
11.1.3 BEIJING WANTAI BIOPHARMACEUTICAL CO., LTD. 235
11.1.3.1 Business overview 235
11.1.3.2 Products offered 236
11.1.3.3 MnM view 236
11.1.3.3.1 Right to win 236
11.1.3.3.2 Strategic choices 236
11.1.3.3.3 Weaknesses & competitive threats 236
11.1.4 SANOFI 237
11.1.4.1 Business overview 237
11.1.4.2 MnM view 239
11.1.4.2.1 Right to win 239
11.1.4.2.2 Strategic choices 239
11.1.4.2.3 Weaknesses & competitive threats 239
11.1.5 ENDO, INC. 240
11.1.5.1 Business overview 240
11.1.5.2 Products offered 241
11.1.5.3 MnM view 241
11.1.5.3.1 Key strengths 241
11.1.5.3.2 Strategic choices 241
11.1.5.3.3 Weaknesses and competitive threats 241
11.1.6 BIOMERIEUX 242
11.1.6.1 Business overview 242
11.1.6.2 Products offered 243
11.1.6.3 Recent developments 244
11.1.6.3.1 Product approvals 244
11.1.7 SD BIOSENSOR, INC. 245
11.1.7.1 Business overview 245
11.1.7.2 Products offered 246
11.1.7.3 Recent developments 246
11.1.7.3.1 Deals 246
11.1.8 LIONEX GMBH 247
11.1.8.1 Business overview 247
11.1.8.2 Products offered 247
11.1.9 SERUM INSTITUTE OF INDIA PVT. LTD. 248
11.1.9.1 Business overview 248
11.1.9.2 Products offered 248
11.1.10 ARKRAY, INC. 249
11.1.10.1 Business overview 249
11.1.10.2 Products offered 249
11.1.10.3 Recent developments 250
11.1.10.3.1 Expansions 250
11.2 OTHER PLAYERS 250
11.2.1 ZHI FEI BIOLOGICAL 250
11.2.2 AID AUTOIMMUN DIAGNOSTIKA GMBH 251
11.2.3 BODITECH MED INC. 251
11.2.4 BIONEOVAN CO., LTD. 252
11.2.5 BIOPANDA REAGENTS LTD. 252
12 APPENDIX 253
12.1 DISCUSSION GUIDE 253
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 257
12.3 CUSTOMIZATION OPTIONS 259
12.4 RELATED REPORTS 259
12.5 AUTHOR DETAILS 260
TABLE 1 LATENT TB TESTING MARKET: RISK ASSESSMENT 41
TABLE 2 COMMERCIALLY AVAILABLE IGRA TESTS, BY KEY PLAYER 51
TABLE 3 AVERAGE SELLING PRICE OF LATENT TB TESTS, 2022-2024 55
TABLE 4 INDICATIVE PRICE OF IGRA TESTS, BY REGION, 2022-2024 56
TABLE 5 LATENT TB TESTING MARKET: LIST OF MAJOR PATENTS, 2022-2023 58
TABLE 6 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION) 62
TABLE 7 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION) 62
TABLE 8 LATENT TB TESTING MARKET: ROLE IN ECOSYSTEM 64
TABLE 9 LATENT TB TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS 64
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS (%) 67
TABLE 11 KEY BUYING CRITERIA FOR LATENT TB TESTS, BY TYPE 68
TABLE 12 CLASSIFICATION OF DEVICES IN EUROPE 69
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 71
TABLE 14 AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES 72
TABLE 15 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 16 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
TABLE 17 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
TABLE 18 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 76
TABLE 19 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 76
TABLE 20 LATENT TB TESTING MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS 78
TABLE 21 LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 91
TABLE 22 LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 91
TABLE 23 BCG VACCINATION COVERAGE, BY REGION, 2021 VS 2022 VS 2023 (%) 93
TABLE 24 COMMERCIALLY AVAILABLE IGRA PRODUCTS, BY COMPANY 93
TABLE 25 LATENT TB TESTING MARKET FOR IGRA, BY REGION, 2022-2029 (USD MILLION) 94
TABLE 26 NORTH AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,
2022-2029 (USD MILLION) 94
TABLE 27 EUROPE: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,
2022-2029 (USD MILLION) 95
TABLE 28 ASIA PACIFIC: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,
2022-2029 (USD MILLION) 95
TABLE 29 LATIN AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,
2022-2029 (USD MILLION) 96
TABLE 30 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022-2029 (USD MILLION) 96
TABLE 31 COMMERCIALLY AVAILABLE TST PRODUCTS IN MARKET, BY COMPANY 97
TABLE 32 LATENT TB TESTING MARKET FOR TST, BY REGION, 2022-2029 (USD MILLION) 98
TABLE 33 NORTH AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,
2022-2029 (USD MILLION) 98
TABLE 34 EUROPE: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,
2022-2029 (USD MILLION) 99
TABLE 35 ASIA PACIFIC: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,
2022-2029 (USD MILLION) 99
TABLE 36 LATIN AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,
2022-2029 (USD MILLION) 100
TABLE 37 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022-2029 (USD MILLION) 100
TABLE 38 LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 102
TABLE 39 LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY REGION,
2022-2029 (USD MILLION) 103
TABLE 40 NORTH AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,
BY COUNTRY, 2022-2029 (USD MILLION) 104
TABLE 41 EUROPE: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,
BY COUNTRY, 2022-2029 (USD MILLION) 104
TABLE 42 ASIA PACIFIC: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,
BY COUNTRY, 2022-2029 (USD MILLION) 105
TABLE 43 LATIN AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,
BY COUNTRY, 2022-2029 (USD MILLION) 105
TABLE 44 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022-2029 (USD MILLION) 106
TABLE 45 LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY REGION, 2022-2029 (USD MILLION) 108
TABLE 46 NORTH AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION) 108
TABLE 47 EUROPE: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION) 109
TABLE 48 ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION) 109
TABLE 49 LATIN AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION) 110
TABLE 50 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION) 110
TABLE 51 LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY REGION,
2022-2029 (USD MILLION) 111
TABLE 52 NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 112
TABLE 53 EUROPE: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 112
TABLE 54 ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 55 LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 56 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 114
TABLE 57 LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 116
TABLE 58 LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION) 118
TABLE 59 NORTH AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 60 EUROPE: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES,
BY COUNTRY, 2022-2029 (USD MILLION) 119
TABLE 61 ASIA PACIFIC: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES,
BY COUNTRY, 2022-2029 (USD MILLION) 119
TABLE 62 LATIN AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 63 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 64 US: NUMBER OF COMMUNITY HOSPITALS, 2020 -VS 2021 122
TABLE 65 LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION,
2022-2029 (USD MILLION) 122
TABLE 66 NORTH AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 67 EUROPE: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION) 123
TABLE 68 ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2029 (USD MILLION) 123
TABLE 69 LATIN AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022-2029 (USD MILLION) 124
TABLE 70 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION) 124
TABLE 71 LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2022-2029 (USD MILLION) 125
TABLE 72 NORTH AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 73 EUROPE: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 126
TABLE 74 ASIA PACIFIC: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 126
TABLE 75 LATIN AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 127
TABLE 76 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 127
TABLE 77 LATENT TB TESTING MARKET FOR OTHER END USERS, BY REGION,
2022-2029 (USD MILLION) 128
TABLE 78 NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 79 EUROPE: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 80 ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 81 LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 82 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 83 LATENT TB TESTING MARKET, BY REGION, 2022-2029 (USD MILLION) 132
TABLE 84 NORTH AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET 134
TABLE 85 NORTH AMERICA: LATENT TB TESTING MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 135
TABLE 86 NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 135
TABLE 87 NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 135
TABLE 88 NORTH AMERICA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 136
TABLE 89 NORTH AMERICA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 136
TABLE 90 US: MAIN TB/LTBI INSTITUTIONS 138
TABLE 91 US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 138
TABLE 92 US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 139
TABLE 93 US: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 139
TABLE 94 US: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 139
TABLE 95 CANADA: MAIN TB/LTBI INSTITUTIONS 141
TABLE 96 CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 141
TABLE 97 CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 141
TABLE 98 CANADA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 142
TABLE 99 CANADA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 142
TABLE 100 ASIA PACIFIC: MACROECONOMIC INDICATORS FOR LATENT TB TESTING MARKET 144
TABLE 101 ASIA PACIFIC: LATENT TB TESTING MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 145
TABLE 102 ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 145
TABLE 103 ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 145
TABLE 104 ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 146
TABLE 105 ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 146
TABLE 106 CHINA: MAIN TB/LTBI INSTITUTIONS 147
TABLE 107 CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 148
TABLE 108 CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 148
TABLE 109 CHINA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 148
TABLE 110 CHINA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 149
TABLE 111 JAPAN: MAIN TB/LTBI INSTITUTIONS 150
TABLE 112 JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 150
TABLE 113 JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 150
TABLE 114 JAPAN: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 151
TABLE 115 JAPAN: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 151
TABLE 116 INDIA: MAIN TB/LTBI INSTITUTIONS 153
TABLE 117 INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 153
TABLE 118 INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 153
TABLE 119 INDIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 154
TABLE 120 INDIA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 154
TABLE 121 SOUTH KOREA: MAIN TB/LTBI INSTITUTIONS 155
TABLE 122 SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 156
TABLE 123 SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 156
TABLE 124 SOUTH KOREA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 156
TABLE 125 SOUTH KOREA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 157
TABLE 126 AUSTRALIA: MAIN TB/LTBI INSTITUTIONS 158
TABLE 127 AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 158
TABLE 128 AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 158
TABLE 129 AUSTRALIA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 159
TABLE 130 AUSTRALIA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 159
TABLE 131 SINGAPORE: MAIN TB/LTBI INSTITUTIONS 160
TABLE 132 SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 160
TABLE 133 SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 161
TABLE 134 SINGAPORE: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 161
TABLE 135 SINGAPORE: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 161
TABLE 136 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 162
TABLE 137 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 163
TABLE 138 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 163
TABLE 139 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 163
TABLE 140 EUROPE: MACROINDICATORS FOR LATENT TB TESTING MARKET 165
TABLE 141 EUROPE: LATENT TB TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 165
TABLE 142 EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 166
TABLE 143 EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 166
TABLE 144 EUROPE: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 166
TABLE 145 EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 167
TABLE 146 UK: MAIN TB/LTBI INSTITUTIONS 168
TABLE 147 UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 168
TABLE 148 UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 168
TABLE 149 UK: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 169
TABLE 150 UK: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 169
TABLE 151 FRANCE: MAIN TB/LTBI INSTITUTIONS 170
TABLE 152 FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 170
TABLE 153 FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 170
TABLE 154 FRANCE: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 171
TABLE 155 FRANCE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 171
TABLE 156 GERMANY: MAIN TB/LTBI INSTITUTIONS 172
TABLE 157 GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 172
TABLE 158 GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 173
TABLE 159 GERMANY: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 173
TABLE 160 GERMANY: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 173
TABLE 161 SPAIN: MAIN TB/LTBI INSTITUTIONS 174
TABLE 162 SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 174
TABLE 163 SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 175
TABLE 164 SPAIN: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 175
TABLE 165 SPAIN: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 175
TABLE 166 ITALY: MAIN TB/LTBI INSTITUTIONS 176
TABLE 167 ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 176
TABLE 168 ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 177
TABLE 169 ITALY: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 177
TABLE 170 ITALY: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 177
TABLE 171 BELGIUM: MAIN TB/LTBI INSTITUTIONS 178
TABLE 172 BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 178
TABLE 173 BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 179
TABLE 174 BELGIUM: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 179
TABLE 175 BELGIUM: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 179
TABLE 176 SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 180
TABLE 177 SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 181
TABLE 178 SWEDEN: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 181
TABLE 179 SWEDEN: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 181
TABLE 180 DENMARK: MAIN TB/LTBI INSTITUTIONS 182
TABLE 181 DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 182
TABLE 182 DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 183
TABLE 183 DENMARK: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 183
TABLE 184 DENMARK: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 183
TABLE 185 REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 184
TABLE 186 REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 185
TABLE 187 REST OF EUROPE: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 185
TABLE 188 REST OF EUROPE: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 185
TABLE 189 LATIN AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET 187
TABLE 190 LATIN AMERICA: LATENT TB TESTING MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 187
TABLE 191 LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 188
TABLE 192 LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 188
TABLE 193 LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 188
TABLE 194 LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 189
TABLE 195 BRAZIL: MAIN TB/LTBI INSTITUTIONS 190
TABLE 196 BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 190
TABLE 197 BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 190
TABLE 198 BRAZIL: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 191
TABLE 199 BRAZIL: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 191
TABLE 200 MEXICO: MAIN TB/LTBI INSTITUTIONS 192
TABLE 201 MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 192
TABLE 202 MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 193
TABLE 203 MEXICO: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 193
TABLE 204 MEXICO: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 193
TABLE 205 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 194
TABLE 206 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 195
TABLE 207 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 195
TABLE 208 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 195
TABLE 209 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 197
TABLE 210 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 197
TABLE 211 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 197
TABLE 212 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 198
TABLE 213 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 198
TABLE 214 SOUTH AFRICA: MAIN TB/LTBI INSTITUTIONS 199
TABLE 215 SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 200
TABLE 216 SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 200
TABLE 217 SOUTH AFRICA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 200
TABLE 218 SOUTH AFRICA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 201
TABLE 219 SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (USD MILLION) 202
TABLE 220 SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE,
2022-2029 (IN MILLIONS) 202
TABLE 221 SAUDI ARABIA: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 202
TABLE 222 SAUDI ARABIA: LATENT TB TESTING MARKET, BY END USER,
2022-2029 (USD MILLION) 203
TABLE 223 UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 204
TABLE 224 UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 204
TABLE 225 UAE: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 204
TABLE 226 UAE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 205
TABLE 227 KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 206
TABLE 228 KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 206
TABLE 229 KUWAIT: LATENT TB TESTING MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 206
TABLE 230 KUWAIT: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 207
TABLE 231 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION) 208
TABLE 232 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS) 208
TABLE 233 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 208
TABLE 234 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION) 209
TABLE 235 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 210
TABLE 236 LATENT TB TESTING MARKET: DEGREE OF COMPETITION 213
TABLE 237 LATENT TB TESTING MARKET: TEST TYPE FOOTPRINT 218
TABLE 238 LATENT TB TESTING MARKET: APPLICATION FOOTPRINT 218
TABLE 239 LATENT TB TESTING MARKET: REGION FOOTPRINT 219
TABLE 240 LATENT TB TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 221
TABLE 241 LATENT TB TESTING MARKET: COMPETITIVE BENCHMARKING
OF STARTUP/SME PLAYERS 221
TABLE 242 LATENT TB TESTING MARKET: PRODUCT LAUNCHES,
JANUARY 2021-SEPTEMBER 2024 224
TABLE 243 LATENT TB TESTING MARKET: DEALS, JANUARY 2021-SEPTEMBER 2024 225
TABLE 244 QIAGEN: COMPANY OVERVIEW 227
TABLE 245 QIAGEN: PRODUCTS OFFERED 228
TABLE 246 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024 229
TABLE 247 QIAGEN: DEALS, JANUARY 2021-SEPTEMBER 2024 229
TABLE 248 QIAGEN: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024 230
TABLE 249 REVVITY: COMPANY OVERVIEW 231
TABLE 250 REVVITY: PRODUCTS OFFERED 232
TABLE 251 REVVITY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024 233
TABLE 252 BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY OVERVIEW 235
TABLE 253 BEIJING WANTAI BIOPHARMACEUTICAL: PRODUCTS OFFERED 236
TABLE 254 SANOFI: COMPANY OVERVIEW 237
TABLE 255 SANOFI: PRODUCTS OFFERED 238
TABLE 256 ENDO: COMPANY OVERVIEW 240
TABLE 257 ENDO: PRODUCTS OFFERED 241
TABLE 258 BIOMERIEUX: COMPANY OVERVIEW 242
TABLE 259 BIOMERIEUX: PRODUCTS OFFERED 243
TABLE 260 BIOMERIEUX: PRODUCT APPROVALS, JANUARY 2021-SEPTEMBER 2024 244
TABLE 261 SD BIOSENSOR: COMPANY OVERVIEW 245
TABLE 262 SD BIOSENSOR: PRODUCTS OFFERED 246
TABLE 263 SD BIOSENSOR: DEALS, JANUARY 2021-SEPTEMBER 2024 246
TABLE 264 LIONEX GMBH: COMPANY OVERVIEW 247
TABLE 265 LIONEX GMBH: PRODUCTS OFFERED 247
TABLE 266 SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW 248
TABLE 267 SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED 248
TABLE 268 ARKRAY: COMPANY OVERVIEW 249
TABLE 269 ARKRAY: PRODUCTS OFFERED 249
TABLE 270 ARKRAY: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024 250
FIGURE 1 LATENT TB TESTING MARKET: RESEARCH DESIGN 29
FIGURE 2 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
FIGURE 3 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
FIGURE 4 LATENT TB TESTING MARKET: TOP-DOWN APPROACH 38
FIGURE 5 LATENT TB TESTING MARKET: DATA TRIANGULATION 39
FIGURE 6 LATENT TB TESTING MARKET: STUDY ASSUMPTIONS 40
FIGURE 7 LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION) 42
FIGURE 8 LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 43
FIGURE 9 LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 43
FIGURE 10 LATENT TB TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 44
FIGURE 11 INCREASING PREVALENCE OF LATENT TB AND GROWING FINANCIAL
SUPPORT FOR TB CONTROL TO DRIVE MARKET 46
FIGURE 12 IGRA WILL CONTINUE TO DOMINATE MARKET TILL 2029 46
FIGURE 13 PEOPLE LIVING WITH HIV SEGMENT TO HOLD LARGEST MARKET SHARE 47
FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO RETAIN DOMINANT
MARKET SHARE TILL 2029 47
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH 48
FIGURE 16 LATENT TB TESTING MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 49
FIGURE 17 PATENT ANALYSIS FOR LATENT TB TESTS (JANUARY 2014-DECEMBER 2023) 57
FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 59
FIGURE 19 LATENT TB TESTING MARKET: SUPPLY CHAIN ANALYSIS 60
FIGURE 20 LATENT TB TESTING MARKET: ECOSYSTEM ANALYSIS 63
FIGURE 21 LATENT TB TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS 65
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS 67
FIGURE 23 KEY BUYING CRITERIA FOR LATENT TB TESTS 67
FIGURE 24 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79
FIGURE 25 DEALS AND FUNDING IN LATENT TB TESTING MARKET 80
FIGURE 26 MARKET POTENTIAL OF AI TO ENHANCE R&D IN LATENT TB TESTING MARKET 88
FIGURE 27 NORTH AMERICA: LATENT TB TESTING MARKET SNAPSHOT 134
FIGURE 28 ASIA PACIFIC: LATENT TB TESTING MARKET SNAPSHOT 144
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN LATENT TB TESTING MARKET
(2021-2023) 212
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LATENT TB
TESTING MARKET (2023) 213
FIGURE 31 NORTH AMERICA: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 215
FIGURE 32 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 215
FIGURE 33 ASIA PACIFIC: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 216
FIGURE 34 LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 217
FIGURE 35 LATENT TB TESTING MARKET: COMPANY FOOTPRINT 218
FIGURE 36 LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 220
FIGURE 37 EV/EBITDA OF KEY VENDORS 222
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 222
FIGURE 39 BRAND COMPARISON FOR IGRA 223
FIGURE 40 QIAGEN: COMPANY SNAPSHOT (2023) 228
FIGURE 41 REVVITY: COMPANY SNAPSHOT (2023) 232
FIGURE 42 BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY SNAPSHOT (2023) 235
FIGURE 43 SANOFI: COMPANY SNAPSHOT (2023) 238
FIGURE 44 ENDO: COMPANY SNAPSHOT (2023) 240
FIGURE 45 BIOMERIEUX: COMPANY SNAPSHOT (2023) 243
FIGURE 46 SD BIOSENSOR: COMPANY SNAPSHOT (2023) 245
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security